N R Williams1, B S Bentzley1, G L Sahlem2, J Pannu1, J E Korte3, G Revuelta4, E B Short2, M S George4,2,5. 1. Department of Psychiatry & Behavioral Sciences, Stanford University, Stanford, CA, USA. 2. Department of Psychiatry, Medical University of South Carolina, Charleston, SC, USA. 3. Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA. 4. Department of Neurology, Medical University of South Carolina, Charleston, SC, USA. 5. Ralph H. Johnson VA Medical Center, Charleston, SC, USA.
Abstract
OBJECTIVES: Electroconvulsive therapy (ECT) has demonstrated efficacy in treating core symptoms of Parkinson's disease (PD); however, widespread use of ECT in PD has been limited due to concern over cognitive burden. We investigated the use of a newer ECT technology known to have fewer cognitive side effects (right unilateral [RUL] ultra-brief pulse [UBP]) for the treatment of medically refractory psychiatric dysfunction in PD. MATERIALS AND METHODS: This open-label pilot study included 6 patients who were assessed in the motoric, cognitive, and neuropsychiatric domains prior to and after RUL UBP ECT. Primary endpoints were changes in total score on the HAM-D-17 and GDS-30 rating scales. RESULTS: Patients were found to improve in motoric and psychiatric domains following RUL UBP ECT without cognitive side effects, both immediately following ECT and at 1-month follow-up. CONCLUSIONS: This study demonstrates that RUL UBP ECT is safe, feasible, and potentially efficacious in treating multiple domains of PD, including motor and mood, without clear cognitive side effects.
OBJECTIVES: Electroconvulsive therapy (ECT) has demonstrated efficacy in treating core symptoms of Parkinson's disease (PD); however, widespread use of ECT in PD has been limited due to concern over cognitive burden. We investigated the use of a newer ECT technology known to have fewer cognitive side effects (right unilateral [RUL] ultra-brief pulse [UBP]) for the treatment of medically refractory psychiatric dysfunction in PD. MATERIALS AND METHODS: This open-label pilot study included 6 patients who were assessed in the motoric, cognitive, and neuropsychiatric domains prior to and after RUL UBP ECT. Primary endpoints were changes in total score on the HAM-D-17 and GDS-30 rating scales. RESULTS:Patients were found to improve in motoric and psychiatric domains following RUL UBP ECT without cognitive side effects, both immediately following ECT and at 1-month follow-up. CONCLUSIONS: This study demonstrates that RUL UBP ECT is safe, feasible, and potentially efficacious in treating multiple domains of PD, including motor and mood, without clear cognitive side effects.
Authors: K Andersen; J Balldin; C G Gottfries; A K Granérus; K Modigh; L Svennerholm; A Wallin Journal: Acta Neurol Scand Date: 1987-09 Impact factor: 3.209
Authors: Gerard Sanacora; Graeme F Mason; Douglas L Rothman; Fahmeed Hyder; James J Ciarcia; Robert B Ostroff; Robert M Berman; John H Krystal Journal: Am J Psychiatry Date: 2003-03 Impact factor: 18.112
Authors: Sarra Nazem; Andrew D Siderowf; John E Duda; Tom Ten Have; Amy Colcher; Stacy S Horn; Paul J Moberg; Jayne R Wilkinson; Howard I Hurtig; Matthew B Stern; Daniel Weintraub Journal: J Am Geriatr Soc Date: 2008-12-10 Impact factor: 5.562
Authors: Harold A Sackeim; Joan Prudic; Mitchell S Nobler; Linda Fitzsimons; Sarah H Lisanby; Nancy Payne; Robert M Berman; Eva-Lotta Brakemeier; Tarique Perera; D P Devanand Journal: Brain Stimul Date: 2008-04 Impact factor: 8.955
Authors: G S Figiel; M A Hassen; C Zorumski; K R Krishnan; P M Doraiswamy; M R Jarvis; D S Smith Journal: J Neuropsychiatry Clin Neurosci Date: 1991 Impact factor: 2.198